Paul Cheng

Pegylated Recombinant Human Arginase (rhArg-peg5,000mw) Inhibits the <i>In vitro</i> and <i>In vivo</i> Proliferation of Human Hepatocellular Carcinoma through Arginine Depletion

Paul Cheng, Alan Tin‐Lun Lam, Wai-Man Lam et al. · Cancer Research · 2007 · 281 citations · Full text

Medicine, Oncology, Pharmacology +13

Targeting the arginine metabolic brake enhances immunotherapy for leukaemia

Francis Mussai, Rachel Wheat, Evgenia Sarrou et al. · International Journal of Cancer · 2018 · 81 citations · Full text

Life Sciences, Immunology, Oncology +17

Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma

Thomas Yau, Paul Cheng, Pierre Chan et al. · Investigational New Drugs · 2015 · 80 citations

Medicine, Oncology, Pharmacology +8

Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma

Paul Cheng, Yun‐Chung Leung, Wai‐Hung Lo et al. · Cancer Letters · 2004 · 64 citations

Medicine, Oncology, Pharmacology +16

Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer.

Young Y. Wang, Francis P. Kuhajda, Jinong Li et al. · PubMed · 2004 · 49 citations

Life Sciences, Cell Biology, Oncology +8